BeiGene markets two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. BeiGene also markets or plans to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Changping District, Beijing, 102206